Latest Manufacturing News

Audeara Ltd reported a strong Q2 FY26 with revenues up 274% year-on-year, securing key regulatory approval in China and expanding its global licensing footprint.

Firebrick Pharma has introduced its Nasodine Throat Spray in Singapore, marking its first international product launch and setting the stage for further global rollouts in 2026.

Telix Pharmaceuticals has met its upgraded FY 2025 revenue guidance with US$804 million, driven by strong growth in its Precision Medicine segment and the successful US launch of Gozellix. The company also advanced multiple clinical trials and announced a strategic collaboration with Varian to combine radiopharmaceuticals with radiation therapy.

Fulcrum Lithium has secured permits for an extensive Phase 3 drilling program at its Alkali Flats project in Nevada, aiming to expand and refine its lithium resource amid a robust market rally.

ARB Corporation’s half-year results reveal a modest sales dip driven by Australian OEM challenges, while robust US export growth offers a silver lining.

Nanoveu Limited has raised A$7.5 million through a strategic placement to accelerate the commercial rollout of its cutting-edge EMASS ECS-DoT semiconductor technology, including a rapid 16nm chip tape-out and live drone validation.

FBR Limited has secured a binding conditional purchase order worth AUD 990,000 from a leading US heavy equipment dealer for its Mantis welding robot, marking a significant milestone during its prototyping phase.

Australian Rare Earths has demonstrated a low-risk, scalable process producing a high-purity mixed rare earth oxide with 99.9% recovery, positioning its Koppamurra project as a strategic supplier amid tightening global rare earth markets.

Mastermyne Group has extended its exclusive distribution agreement with Jennmar Holdings for critical strata consolidation products by a decade, locking in supply until 2047. This move strengthens its foothold in the Australian underground coal mining sector.

Vinyl Group Ltd has reported a landmark quarter with record cash receipts up 80% quarter-on-quarter and its first operating cash flow positive result, signalling a turning point for the music and culture company.

Cambium Bio has locked in a A$2.4 million strategic investment from Zheng Yang Biomedical Technology, reinforcing its push into pivotal Phase 3 trials for its dry eye disease treatment.

Fletcher Building has agreed to sell its Construction Division to global giant VINCI Construction for an initial $315.6 million, with potential to rise to $334.1 million. The move marks a strategic pivot towards focused building products manufacturing.